Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
leucovorin + fluorouracil + oxaliplatin + QL1706 + cetuximab
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This combination therapy is an investigational chemo-immunotherapy regimen being evaluated for the first-line treatment of metastatic colorectal cancer (mCRC). It consists of the standard FOLFOX chemotherapy backbone (oxaliplatin, leucovorin, and fluorouracil), the EGFR-targeting monoclonal antibody cetuximab, and QL1706. QL1706 is a novel bifunctional antibody (MabPair) that simultaneously targets programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). The regimen is specifically being studied in patients with RAS/BRAF wild-type, left-sided primary tumors, where EGFR inhibition is typically more effective. The combination aims to leverage the cytotoxic effects of chemotherapy, the targeted inhibition of EGFR signaling, and the dual checkpoint blockade of PD-1 and CTLA-4 to enhance anti-tumor immune responses and improve clinical outcomes.
- Other names
- FOLFOX-QL1706-CetuximabFOLFOX-QL-1706-CetuximabFOLFOX-QL 1706-CetuximabQL1706 plus FOLFOX and CetuximabQL-1706 plus FOLFOX and CetuximabQL 1706 plus FOLFOX and Cetuximab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNAEGFR (Epidermal growth factor receptor)PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)
Beyond the preview
Go deeper on leucovorin + fluorouracil + oxaliplatin + QL1706 + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on leucovorin + fluorouracil + oxaliplatin + QL1706 + cetuximab.